This revolutionary startup innovates existing molecular testing workflows by introducing the SaaS method

This article is exclusively shared by the Founder of Algorithmic Biologics with Marketing In Asia.

This revolutionary startup innovates existing molecular testing workflows by introducing the SaaS method

Molecular Testing is a $62 Billion industry that's being affected by innovative companies who are interested in scaling up the business. Apart from the diagnostic services, manufacturers of reagents, assays, kits, and machine manufacturers, it consists of scale multiplier technologies which form 15% of the market and is growing at a CAGR of 15%. 

Algorithmic Biologics is the only team from India to reach the finals of the international XPRIZE competition for rapid Covid Testing was founded by Dr Manoj Gopalkrishnan, a faculty member at IIT Bombay's Center for Machine Intelligence & Data Science. Algorithmic Biologics improves the power and efficiency of the existing assays by 10X using their algorithms.

"Biology is what emerges when Chemistry performs Algorithms," the team at Algorithmic Biologics says.

The only way to remain ahead of the competition is by bringing in new ways of testing which can also pose a big challenge. But this isn't an obstacle preventing innovation because it's only bringing the market closer together to create something that's never been done before.

"We are introducing a new algorithmic approach on top of existing workflows which helps to improve their power and efficiency. We are aiming for a leadership position in this segment in the next three years." Dr. Manoj

How Do They Create A New Algorithmic Approach? 

Algorithmic Biologics brings coding and compression algorithms to molecular information while other companies test molecular knowledge in the lab or use automation. The solution? An algorithmic process that delivers our results as a service with no installation required. Moreover, their customers are scientists working with molecular information like biologists, chemists, and chemical engineers.

"There has been a massive increase in Biotech investment. A new wave of technology-first biotech companies emerged and focused on reinventing multiple trillion-dollar industries like textiles, chemicals, and construction. We see ourselves as catalyzing and accelerating discovery and innovation for these new startups by relieving the molecular testing bottleneck."

Unique Offerings-

"Our innovation has been featured in the international scientific press including Nature magazine, Institute of Electrical and Electronics Engineers, American Mathematical Society, and Society for Industrial and Applied Mathematics." says founder Dr. Manoj Gopalkrishnan.

Biotech innovation has slowed down in recent years because it can take decades and millions of dollars to bring this to market. Fortunately, Algorithmic Biologics wants to make innovation in biology as easy as writing an app. With the help of their software, you can now determine what kind of molecules will treat disease by testing hypotheses for a fraction of the cost and time it takes right now - and all without going broke! 

The Algorithmic Biologics algorithm can reduce assay development time by up to 75%, minimize assay development cost by up to 90%, provide support to many applications though just one app and do so much more!  

The Story Behind The Name 'Algorithmic Biologics' - 

Biologics are a kind of molecule found in living systems. Your body's intelligence consists of living Biologics working together through biochemical circuits that perform algorithms. The name "Algorithmic Biologics" signifies that we work with Biologics and build Algorithms to program them, thus obtaining intelligent behavior from non-living systems.

What Does The Future Look Like? 

Biology as technology is coming soon, and soon they will be able to engineer living beings that do anything! This means that they can treat diseases and stop the food shortage by looking for crops more suitable to local conditions. Algorithmic Biologics can even turn non-renewable fossil fuels into sustainable biofuels.

Says Dr. Manoj -  "We are a platform company for this revolution. We are putting down the bricks integrating algorithms and biologics on top of which multiple new-age companies will build. "

With the advent of powerful drugs, age-related ailments treat with medication, just like the treatment for cancer and other disorders we currently deal with today. In addition to this, the food grown in vats will replace farms that rely on animals or plants to produce food, creating an environment unattractive to insects. 

"We are building a molecular computing platform to deliver these solutions at scale. We rolled out the first solution for Covid Testing and are since working on offering commercial solutions in more verticals, and growing in each vertical through channel partners." director Dr. Manoj Gopalkrishnan further added, "Another dimension of growth is growing in multiple geographies, leveraging our SaaS solution. "

Revenue Model-

"While we are innovating at a deep science stage to deliver value to our customers, our service delivery and revenue model is effortless and designed along the lines of SaaS."

Algorithmic Biologics is now in the early revenue stage and growing at an accelerating rate by expanding existing services and rolling out new industry verticals. Sit tight because even more changes are coming within the next couple of quarters.

"Scale multiplier technologies for food safety is our beachhead market," claimed Dr. Manoj

Who Are The Other Player In The Industry?

Many technology solutions are playing in the automation, biology, and chemical assay space, innovating rapidly to increase efficiency. Opentrons, Labcyte, and Illumina, for instance, have helped to skyrocket the industry by creating a wide range of automated instrumentation for laboratories. And then there's Oxford Nanopore – pioneering the next generation of DNA sequencing – as well as TwistDx and 10XGenomics in biological and chemical assays, respectively.

The Scalability Model- 

Algorithmic Biologics are looking to grow through channel partners since their core DNA technology innovation and selling a single product in different markets. 

"We have an R&D pipeline to innovate and take the innovations to solutions like running joint pilots with industry leaders to prove commercial benefits to customers. We often work with channel partners to scale up the product while we stay engaged for customer success."

The Team That Made It Happen-

The team at Algorithmic Biologics is full of experience-rich individuals having gained expansive knowledge over the course of their educational and professional career. 

  • Dr. Manoj Gopalkrishnan serves as a faculty member at IIT Bombay's Center for Machine Intelligence & Data Science. After completing his B.Tech from IIT Kharagpur, he graduated with a Ph.D. in Computer Science. 
  • CBO- Nidhi Mathur is a Venture Partner at Axilor and a graduate of IIM Bangalore. 
  • Co-founder and COO of Niramai, she has been active in health-tech startups for six years.
  • Yuanfang Xie is a Data Scientist at ABPL with experience in data science, mathematical modelling, and signal processing.
  • Solutions Architect- Krishna Vishal Vemula holds a BTech in Applied Mathematics from IIT Madras. Starting as an outstanding volunteer for our Covid19 screening project, he later moved to a full-time position at ABPL.
  • Shampa Singh is a product manager with six years of experience as a product manager in leading product-driven startups and is currently working on Wysa. She holds a Master's degree in Biological Sciences from TIFR Mumbai and a Postgraduate Diploma in Liberal Arts from Ashoka University.
  • Dr. Mandar Phatak, the molecular science specialist, holds a PhD in biology from TIFR Mumbai and an MSc in Biotechnology from Pune University. His Master's thesis was also on synthetic biology. He was awarded a bronze medal at MIT in the 2017 top synthetic biology competition, iGEM. Prantik, the data engineer, received his B. Tech. in Chemical Engineering from IIT Bombay, and he's passionate about both software and fundamental and interdisciplinary scientific endeavours.
  • Dr. Alankrita Priya, the data scientist, specializes in data science and physics-based modeling. She received a PhD in physics from Arizona State University and a BS / MS dual degree in physics from the Indian Institute of Science Education and Research, Bhopal.